New Treatment Strategies in Metastatic Lung Cancer
by Ramaswamy Govindan, MD
Publisher: CMPMedica
Number Of Pages: 148
Publication Date: 2008
ISBN-10 / ASIN: 9781891483585
Binding: Paperback
Even the most skeptical among us would agree that we have made
progress in the treatment of metastatic nonsmall-cell lung cancer
(NSCLC) over the past decade. The early 1990s witnessed the arrival of
kinder and gentler chemotherapy regimens ably supported by very effective
anti-nausea medications resulting in modest improvement in the outcomes.
The introduction of novel molecular targeted agents, led initially by gefitinib
and followed now by several other agents inhibiting different pathways,
has opened a new avenue for therapy and hope. Targeted therapy is
now a reality not only for patients with advanced NSCLC progressing
after chemotherapy but also in the front-line setting (for a select group of
patients) with bevacizumab, an inhibitor of anti-angiogenic therapy. With
all these new developments (and more), the treatment of advanced NSCLC
is now quite challenging and constantly changing.
It is my distinct pleasure and privilege to present you an up-to-date
monograph on the contemporary (2008) management of metastatic
NSCLC. This monograph, as with our other monographs in this series, is
intended to guide the practicing oncologists in the community. The practical
advice that you will get from this panel of experts flows not only from a
wealth of research experience, but is also seasoned very well by years of
clinical experience. Apart from covering the management of advanced
NSCLC in the first- and second-line setting and beyond with cytotoxic chemotherapy
and molecular targeted therapy, we have included two interesting
sections, one on the management of the ubiquitous rash secondary to
epidermal growth factor receptor therapy and another on the curative
options for metastatic NSCLC.
The two words curative and metastatic
may not have gone into one sentence regarding NSCLC 10 years ago, but
we are now emboldened to think about this possibility, even though only
for a rare patient. That is definitely a sign of changing times.
http://www.book4doc.com/20990
http://www.book4doc.com/23152
http://www.book4doc.com/49413
by Ramaswamy Govindan, MD
Publisher: CMPMedica
Number Of Pages: 148
Publication Date: 2008
ISBN-10 / ASIN: 9781891483585
Binding: Paperback
Even the most skeptical among us would agree that we have made
progress in the treatment of metastatic nonsmall-cell lung cancer
(NSCLC) over the past decade. The early 1990s witnessed the arrival of
kinder and gentler chemotherapy regimens ably supported by very effective
anti-nausea medications resulting in modest improvement in the outcomes.
The introduction of novel molecular targeted agents, led initially by gefitinib
and followed now by several other agents inhibiting different pathways,
has opened a new avenue for therapy and hope. Targeted therapy is
now a reality not only for patients with advanced NSCLC progressing
after chemotherapy but also in the front-line setting (for a select group of
patients) with bevacizumab, an inhibitor of anti-angiogenic therapy. With
all these new developments (and more), the treatment of advanced NSCLC
is now quite challenging and constantly changing.
It is my distinct pleasure and privilege to present you an up-to-date
monograph on the contemporary (2008) management of metastatic
NSCLC. This monograph, as with our other monographs in this series, is
intended to guide the practicing oncologists in the community. The practical
advice that you will get from this panel of experts flows not only from a
wealth of research experience, but is also seasoned very well by years of
clinical experience. Apart from covering the management of advanced
NSCLC in the first- and second-line setting and beyond with cytotoxic chemotherapy
and molecular targeted therapy, we have included two interesting
sections, one on the management of the ubiquitous rash secondary to
epidermal growth factor receptor therapy and another on the curative
options for metastatic NSCLC.
The two words curative and metastatic
may not have gone into one sentence regarding NSCLC 10 years ago, but
we are now emboldened to think about this possibility, even though only
for a rare patient. That is definitely a sign of changing times.
http://www.book4doc.com/20990
http://www.book4doc.com/23152
http://www.book4doc.com/49413
No comments:
Post a Comment